Elamipretide (intermediate dose) (DrugBank: Elamipretide)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 21 | Mitochondrial disease | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02367014 (ClinicalTrials.gov) | February 2015 | 9/2/2015 | Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy | Phase 1/2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending-Dose Clinical Study for the Safety, Tolerability, and Efficacy of IV MTP-131 for Mitochondrial Myopathy in Genetically Confirmed Mitochondrial Disease | Mitochondrial Myopathy | Drug: elamipretide (low dose);Drug: elamipretide (intermediate dose);Drug: elamipretide (high dose);Drug: Placebo | Stealth BioTherapeutics Inc. | NULL | Completed | 16 Years | 65 Years | All | 36 | Phase 1;Phase 2 | United States |